Cempra is a clinical-stage pharmaceutical company engaged in developing antibiotics to meet critical needs in treating bacterial infectious diseases. The company’s two lead product candidates, solithromycin and CEM-102, are currently in advanced clinical development – both aimed at addressing the … Continue reading →

Inovio Pharmaceuticals is revolutionizing vaccines for the prevention and treatment of today’s cancers and infectious diseases. The company’s SynCon vaccines are designed to provide universal cross-strain protection against both known and newly emergent unmatched strains of pathogens, such as influenza. … Continue reading →

Neuralstem possesses patented technology that enables the production of neural stem cells of the human brain and spinal cord in commercial quantities, as well as the ability to control the differentiation of these cells into mature, physiologically relevant human neurons … Continue reading →

Resverlogix is a clinical-stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is currently developing RVX-208, which is a first-in-class small molecule for treating atherosclerosis and the first BET bromodomain inhibitor in clinical trials. New … Continue reading →

Athersys is a clinical stage biopharmaceutical company focused on discovering and developing therapeutic product candidates for extending and enhancing human quality of life. The company is currently developing its MultiStem cell therapy product and has developed a diverse portfolio of … Continue reading →

ImmunoGen is a biotechnology company developing targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, coupled with its expertise in monoclonal antibodies and tumor biology. A TAP compound delivers one of ImmunoGen’s purpose-developed cancer-killing agents specifically to tumor cells … Continue reading →

Zalicus is a biopharmaceutical company engaged in discovering and developing novel treatments for patients suffering with pain. The company’s portfolio of proprietary clinical-stage product candidates has entered into various revenue-generating collaborations with large pharmaceutical companies relating to other products, product … Continue reading →

Exelixis is a biotechnology company focused on the development of small molecule therapies to treat cancer. The company’s proprietary resources and development efforts are focused exclusively on COMETRIQ, its lead product. The company has additionally established a portfolio of other … Continue reading →

StemCells is a leading developer of cell-based therapeutics and tools for stem cell-based research and drug discovery. StemCells’ lead therapeutic product candidate, HuCNS-SC cells, is currently being developed as a potential treatment for various central nervous system disorders. The company … Continue reading →

Horizon Pharma is a biopharmaceutical company focused on the development and commercialization of innovative medicines to target unmet therapeutic needs in the areas of arthritis, pain and inflammatory diseases. The company’s strategy involves commercializing its products in the United States, … Continue reading →